2021-07-19| Asia-Pacific

CYTENA Launches the Next-Generation Microbioreactor to Revolutionize Cell Culture

by Tyler Chen
Share To

CYTENA Bioprocess Solutions, a CELLINK company, launches S.NEST, a high throughput microbioreactor with a monitoring system that maximizes cell growth, reduces workflow time, and turns data into valuable insights.

Cell culture plays a critical role in drug discovery, selection, and biologics manufacturing. CYTENA emphasized that “S.NEST revolutionizes the way to do cell cultures with its unique technology to increase efficiency and productivity for biologics production, drug screening, and functional genomics studies.”

With the patented reciprocating mixing technology, S.NEST enables cells to grow in suspension cultures with optimal growth space and oxygen supply, releasing the lab from weeks of work for cell upscaling and expansion. 

Its incubation chambers have individual environmental settings and are compatible with four 96-well or 24-well culture plates, demonstrating high cell cultivation. What’s more, the camera module in the microbioreactor provides real-time pH and dissolved oxygen monitoring during cell growth. Besides, the software embedded in the system is able to transform monitored data into research insights, maximizing efficiency and value.

S.NEST™ microbioreactor

The next-generation microbioreactor is an important innovation for cell line development, and it certainly has huge potential in cell culture research. The bioreactor has been testified by worldwide users that it can increase cell growth, delivering better results. In addition, with the real-time monitoring system, S.NEST becomes the next-generation microbioreactor that provides valuable insights to boost cell line development. From now on, S.NEST will continue to upgrade and provide laboratories with highly efficient cell culture breakthroughs.

© All rights reserved. Collaborate with us:
Related Post
CYTENA BPS and Leadgene Bio to Level Up Taiwan’s Protein Drugs Production
CYTENA Bioprocess Solutions Closes $5M Funding to Develop Automatic High-throughput Screening Platform for Pharmaceuticals
Cytena Bioprocess Solutions Closes Pre-A series Funding, Accelerates Development in Microbioreactors
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
Comparing ESG Regulations in the U.S., the U.K., and the EU
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
Scroll to Top